Vantia Therapeutics Publishes The Nocturia Patient Reported Outcome Instrument, Nocturia Treatment Impact Measure, NocTIMe, at the American Urological Association Meeting in San Diego, 2016

Southampton, UK, 9 May 2016 – Vantia Therapeutics announces publication of its patient reported outcome instrument, Nocturia Treatment Impact Measure, "NocTIMe" at the American Urological Association Meeting in San Diego, 2016.

Nocturia is a common condition that causes sufferers to wake frequently during the night in order to urinate ("nocturnal or night-time voids"). Its prevalence and severity increases markedly with age and it is often the presenting symptom in men with BPH (enlarged prostate gland), affecting at least 70% of BPH patients.

Nocturia has a significant detrimental impact on the quality of life in patients. Current instruments used to assess the impact of nocturia on how patients feel and function have limitations and may not be suitable to quantify the effect of treatment on their daily lives. Vantia has developed NocTIMe to meet current regulatory guidelines and support its development of fedovapagon for the treatment of nocturia in men with BPH.

Laurie Burke (LORAgroup LLC), who presented the data at the American Urological Association meeting, said "We are very encouraged by the data generated to date using NocTIMe and hope that its use will help bring treatments forward for patients who suffer the significant impact of nocturia".

NocTIMe was initially developed in a IRB-approved research study conducted in 55 patients with BPH in the US. That study showed that the final instrument contained appropriate content and was able to quantify the impact of nocturia on patients. Vantia has included the NocTIMe in its ongoing EQUINOC pivotal efficacy study evaluating fedovapagon for the treatment if nocturia in men with BPH.

Fedovapagon is a selective, small molecule vasopressin V2 receptor agonist, discovered by Vantia scientists, that has an anti-diuretic effect through stimulation of V2 receptors in the kidney. Preliminary efficacy and safety of fedovapagon, and a dose for the EQUINOC trial, has been established in several completed clinical studies. Top line data from the EQUINOC study is expected in the third quarter of 2017.

Contact details:
Vantia Therapeutics
Stephen Donnelly
+44 (0)238 076 3456 /+44 (0)787 255 9676
info@vantia.com

Citigate Dewe Rogerson
Mark Swallow
+44 (0)207 638 9571
vantia@citigatedr.co.uk

About Vantia Therapeutics:
Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its lead clinical candidate, fedovapagon (VA106483), was discovered by Vantia scientists and is in a pivotal clinical study for the treatment of nocturia in men

with benign prostatic hyperplasia (BPH). The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
www.vantia.com